XML 13 R2.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Balance Sheets (Unaudited) - USD ($)
Mar. 31, 2025
Dec. 31, 2024
Current assets:    
Cash $ 79,173 $ 86,128
Restricted cash 20,000 20,000
Accounts receivable 18,976 18,976
Prepaid & other current assets 6,844 9,107
Total current assets 124,993 134,211
In process R&D 1,101,760 1,101,760
Goodwill, net of impairment 2,788,230 2,788,230
Investment in GMP Bio at fair vlue 22,653,225 22,653,225
Total assets 26,668,208 26,677,426
Current liabilities:    
Accounts payable and accrued liabilities 2,463,305 2,437,167
Contingent consideration 2,625,000 2,625,000
Derivative liability on notes 762,983 703,616
Total current liabilities 19,484,762 19,199,914
Total liabilities 19,484,762 19,199,914
Commitments and contingencies (Note 14)  
Stockholders’ equity:    
Common stock, $.01 par value; 750,000,000 shares authorized; 408,292,720 and 407,289,888 issued and outstanding, respectively 4,082,927 4,072,899
Additional paid-in capital 42,279,570 42,219,400
Accumulated deficit (38,339,384) (38,040,668)
Total Oncotelic Therapeutics, Inc. stockholders’ equity 8,023,113 8,251,631
Non-controlling interests (839,667) (774,119)
Total stockholders’ equity 7,183,446 7,477,512
Total liabilities and stockholders’ equity 26,668,208 26,677,426
Convertible Preferred Stock [Member]    
Stockholders’ equity:    
Convertible preferred stock, $0.01 par value, 15,000,000 shares authorized; 0 shares issued and outstanding
Related Party [Member]    
Current liabilities:    
Accounts payable to related party 346,570 346,057
Convertible debt and short-term debt, net of costs 3,465,421 3,297,208
Nonrelated Party [Member]    
Current liabilities:    
Convertible debt and short-term debt, net of costs $ 9,821,483 $ 9,790,866